Although overall mortality rates for patients with lupus have declined since the turn of the century, racial, sex and ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

Upadacitinib treatment was associated with reduced non-nociceptive pain among patients with axSpA, including both neuropathic ...

In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights a pair of “timely and cool” stories on point-of-care AI use and the FDA approval of ...

Fibromyalgia was considered a comorbidity rather than a rheumatic disease, but was present in about 10% of patients. Other ...

Supporting lupus patients and advocates in Arizona.

Phase III data for dapirolizumab pegol presented at the 2025 American College of Rheumatology showed quality-of-life benefits ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment ...

Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across strict measures of peripheral ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...